Over the last decade, significant advances have been made regarding the knowledge of the biological bases, diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), which currently is the most frequent form of cardiac amyloidosis seen in clinical practice. The possibility of detecting the disease by means of non-invasive cardiac imaging techniques like pyrophosphate scintigraphy [1–3], as well as the availability of novel drugs that may improve survival [4–7], resulted in a substantial increase in the number of patients who are diagnosed and treated of ATTR-CM worldwide.
